老眼 - 市場の洞察、疫学、市場予測：2034年

主要7ヶ国の老眼治療の市場規模は、2023年に約170億米ドルとなりました。米国は、2023年、主要7ヶ国の中で米国が最も大きく、約80億3,900万米ドルを占め、2034年までにさらに増加すると予想されます。欧州諸国の中で、ドイツは2023年に16億6,600万米ドル近くの市場規模を持ち、最も高い市場規模を持つ一方、スペインは2023年に9億3,800万米ドルで、老眼の市場規模が最も小さくなっています。日本の老眼市場規模は2023年に26億4,200万米ドルとなり、主要7ヶ国市場全体の16%を占めました。

老眼は、近見視力の漸進的な低下を特徴とする一般的な加齢に関連した疾患であり、通常40歳以降に顕著になり、40～60歳の間に進行します。このような近見視力の低下は、自然な加齢過程によるもので、水晶体内のタンパク質の加齢変化により目のレンズの弾力性が失われ、レンズが厚くなり、硬くなり、柔軟性がなくなります。これらの変化は、水晶体が光線を適切に屈折させる能力を損ない、目の焦点を合わせる能力を低下させます。老眼は、初期老眼、機能性老眼、絶対老眼、早期老眼、夜間老眼など、いくつかのタイプに分類することができます。老眼の主な危険因子は加齢ですが、外傷、全身疾患、心血管系疾患、薬剤の副作用などの要因により、老眼の症状が早期に現れることもあります。初期症状としては、長時間近くを見る作業が困難になったり、眼精疲労が生じたりすることが多く、薄暗い場所では悪化することがあります。その他の一般的な症状としては、様々な距離でのピント調節の遅れ、眼不快感、頭痛、眼精疲労、目を細めること、近くでの作業による疲労や眠気、作業距離の増加、読書時の明るい光の必要性、複視などがあります。これらのメカニズムと症状を理解することは、老眼の効果的な管理と治療にとって非常に重要です。

老眼の診断には、眼科医による網膜、筋肉の完全性、屈折、細隙灯評価、視野、視力の評価を含む包括的な眼科検査が必要です。検眼鏡を使って網膜、視床、脈絡膜を検査します。筋肉の完全性は、患者が動くものを追う能力を観察することで評価します。屈折検査では、角膜と水晶体を通して光の波がどの程度曲がるかを調べ、正しいレンズ処方を特定します。細隙灯検査では前眼部の構造を拡大して観察し、視野検査では周辺視野を測定し、視力検査ではさまざまな距離の明瞭度を評価します。一時的に光の感受性を高める瞳孔拡張点眼薬を使用することもあります。これらの評価により、正確な診断と眼球の健康全般が保証されます。

老眼の治療には、患者の職業や職業上のニーズに合わせた様々な選択肢があり、近くのものに焦点を合わせる目の能力の低下を補うことを目的としています。光学的な矯正は、矯正眼鏡（メガネレンズ）やコンタクトレンズによって達成することができ、より永続的な解決策を求める人には、屈折矯正手術や水晶体移植が実行可能な選択肢となります。屈折矯正手術には、伝導性角膜形成術、レーシック、ラセック、光屈折矯正術などがあり、技術の進歩により、より安全で効果的になってきています。加えて、現在の臨床管理では、非ステロイド性抗炎症薬（NSAIDs）、副交感神経作動薬、ミオティック剤、および他の緩和剤の適応外使用が行われることがあります。これらの治療でよく使用される薬剤には、ピロカルピン、カルバコール、アセクリジン、ブリモニジン、ネパフェナックなどがあります。それぞれの治療オプションは、患者の特定のニーズと状態に基づいて検討され、老眼を管理するための包括的なアプローチを提供します。

当レポートでは、主要7ヶ国における老眼市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 老眼市場概要

第4章 老眼市場：将来の展望

第5章 老眼のエグゼクティブサマリー

第6章 重要な出来事

第7章 疾患の背景と概要

• 老眼の兆候と症状
• 鑑別診断

第8章 疫学と患者人口

• 疫学の調査手法
• 米国
• EU4ヶ国と英国

第9章 患者動向

第10章 上市済み薬剤

第11章 主要な新興治療法

第12章 老眼：主要7ヶ国市場分析

• 主な調査結果：市場
• 市場見通し
• 主要な市場予測の前提条件
• コンジョイント分析
• 主要7ヶ国における老眼の総市場規模
• 主要7ヶ国における老眼治療市場規模
• 米国
• EU4ヶ国と英国
• 日本

第13章 KOLの見解

第14章 SWOT分析

第15章 アンメットニーズ

第16章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本

第17章 付録

• 文献
• 頭字語と略語

第18章 レポートの調査手法

第19章 DelveInsightのサービス内容

第20章 免責事項

第21章 DelveInsightについて

List of Tables

• Table 1: Summary of Presbyopia, Market, Epidemiology, and Key Events (2020-2034)
• Table 2: Key Events
• Table 3: Common risk factors of presbyopia
• Table 4: Recommended examination frequency for the pediatric patient
• Table 5: Recommended examination frequency for the adult patient
• Table 6: Prescribing Considerations for Presbyopia
• Table 7: Comparison of the guidelines
• Table 8: Total Diagnosed Prevalent Cases of Presbyopia in the 7MM (2020-2034)
• Table 9: Total Prevalent Cases of Presbyopia in the United States (2020-2034)
• Table 10: Total Diagnosed Prevalent Cases of Presbyopia in the United States (2020-2034)
• Table 11: Gender-specific cases of Presbyopia in the United States (2020-2034)
• Table 12: Age-specific cases of Presbyopia in the United States (2020-2034)
• Table 13: Severity-specific cases of Presbyopia in the United States (2020-2034)
• Table 14: Total Prevalent Cases of Presbyopia in Germany (2020-2034)
• Table 15: Total Diagnosed Prevalent Cases of Presbyopia in Germany (2020-2034)
• Table 16: Gender-specific cases of Presbyopia in Germany (2020-2034)
• Table 17: Age-specific cases of Presbyopia in Germany (2020-2034)
• Table 18: Severity-specific cases of Presbyopia in Germany (2020-2034)
• Table 19: Total Prevalent Cases of Presbyopia in France (2020-2034)
• Table 20: Total Diagnosed Prevalent cases of Presbyopia in France (2020-2034)
• Table 21: Gender-specific cases of Presbyopia in France (2020-2034)
• Table 22: Age-specific cases of Presbyopia in France (2020-2034)
• Table 23: Severity-specific cases of Presbyopia in France (2020-2034)
• Table 24: Total Prevalent Cases of Presbyopia in Italy (2020-2034)
• Table 25: Total Diagnosed Prevalent cases of Presbyopia in Italy (2020-2034)
• Table 26: Gender-specific cases of Presbyopia in Italy (2020-2034)
• Table 27: Age-specific cases of Presbyopia in Italy (2020-2034)
• Table 28: Severity-specific cases of Presbyopia in Italy (2020-2034)
• Table 29: Total Prevalent Cases of Presbyopia in Spain (2020-2034)
• Table 30: Total Diagnosed Prevalent cases of Presbyopia in Spain (2020-2034)
• Table 31: Gender-specific cases of Presbyopia in Spain (2020-2034)
• Table 32: Age-specific cases of Presbyopia in Spain (2020-2034)
• Table 33: Severity-specific cases of Presbyopia in Spain (2020-2034)
• Table 34: Total Prevalent Cases of Presbyopia in the United kingdom (2020-2034)
• Table 35: Total Diagnosed Prevalent cases of Presbyopia in the United Kingdom (2020-2034)
• Table 36: Gender-specific Cases of presbyopia in the United Kingdom (2020-2034)
• Table 37: Age-specific Cases of presbyopia in the United Kingdom (2020-2034)
• Table 38: Severity-specific Cases of presbyopia in the United Kingdom (2020-2034)
• Table 39: Total Prevalent Cases of Presbyopia in Japan (2020-2034)
• Table 40: Total Diagnosed Prevalent cases of Presbyopia in Japan (2020-2034)
• Table 41: Gender-specific cases of Presbyopia in Japan (2020-2034)
• Table 42: Age-specific cases of Presbyopia in Japan (2020-2034)
• Table 43: Severity-specific cases of Presbyopia in Japan (2020-2034)
• Table 44: VUITY (pilocarpine HCI ophthalmic solution) 1.25%, Clinical Trials Description, 2024
• Table 45: QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%, Clinical Trials Description, 2024
• Table 46: BRIMOCHOL PF (VT-1011), Clinical Trials Description, 2024
• Table 47: LNZ100 - 1.75% Aceclidine, Clinical Trials Description, 2024
• Table 48: Total Seven Major Market Size, in USD million [2020-2034]
• Table 49: 7MM-Market Size by Therapies, in USD million [2020-2034]
• Table 50: Total Market Size in United States, in USD million [2020-2034]
• Table 51: United States Market Size by Therapies in USD, Million [2020-2034]
• Table 52: Total Market Size in Germany, in USD million [2020-2034]
• Table 53: Germany Market Size by Therapies in USD, Million [2020-2034]
• Table 54: Total Market Size in France , in USD million [2020-2034]
• Table 55: France Market Size by Therapies, in USD million [2020-2034]
• Table 56: Total Market Size in Italy, in USD million [2020-2034]
• Table 57: Italy Market Size by Therapies, in USD million [2020-2034]
• Table 58: Spain Total Market Size, in USD million [2020-2034]
• Table 59: Spain Market Size by Therapies, in USD million [2020-2034]
• Table 60: Total Market Size in the United Kingdom, in USD million [2020-2034]
• Table 61: United Kingdom Market Size by Therapies in USD, Million [2020-2034]
• Table 62: Total Market Size in Japan, in USD million [2020-2034]
• Table 63: Market Size in Japan by Therapies, in USD million [2020-2034]

List of Figures

• Figure 1: Presbyopia compared to a Normal eye
• Figure 2: Symptoms of Presbyopia
• Figure 3: Causes of Presbyopia
• Figure 4: Anatomy of the eye
• Figure 5: Pathogenesis of Presbyopia
• Figure 6: Differential diagnosis of presbyopia
• Figure 7: Treatment Algorithm
• Figure 8: Management of Presbyopia
• Figure 9: Optical correction with spectacle lenses
• Figure 10: Optical correction with contact lenses
• Figure 11: Conductive Keratoplasty
• Figure 12: Total Prevalent Cases of Presbyopia in the United States (2020-2034)
• Figure 13: Total Diagnosed Prevalent Cases of Presbyopia in the United States (2020-2034)
• Figure 14: Gender-specific cases of Presbyopia in the United States (2020-2034)
• Figure 15: Age-specific cases of Presbyopia in the United States (2020-2034)
• Figure 16: Severity-specific cases of Presbyopia in the United States (2020-2034)
• Figure 17: Total Prevalent Cases of Presbyopia in Germany (2020-2034)
• Figure 18: Total Diagnosed Prevalent Cases of Presbyopia in Germany (2020-2034)
• Figure 19: Gender-specific cases of Presbyopia in Germany (2020-2034)
• Figure 20: Age-specific cases of Presbyopia in Germany (2020-2034)
• Figure 21: Severity-specific cases of Presbyopia in Germany (2020-2034)
• Figure 22: Total Prevalent Cases of Presbyopia in France (2020-2034)
• Figure 23: Total Diagnosed Prevalent cases of Presbyopia in France (2020-2034)
• Figure 24: Gender-specific cases of Presbyopia in France (2020-2034)
• Figure 25: Age-specific cases of Presbyopia in France (2020-2034)
• Figure 26: Severity-specific cases of Presbyopia in France (2020-2034)
• Figure 27: Total Prevalent Cases of Presbyopia in Italy (2020-2034)
• Figure 28: Total Diagnosed Prevalent cases of Presbyopia in Italy (2020-2034)
• Figure 29: Gender-specific cases of Presbyopia in Italy (2020-2034)
• Figure 30: Age-specific cases of Presbyopia in Italy (2020-2034)
• Figure 31: Severity-specific cases of Presbyopia in Italy (2020-2034)
• Figure 32: Total Prevalent Cases of Presbyopia in Spain (2020-2034)
• Figure 33: Total Diagnosed Prevalent cases of Presbyopia in Spain (2020-2034)
• Figure 34: Gender-specific cases of Presbyopia in Spain (2020-2034)
• Figure 35: Age-specific cases of Presbyopia in Spain (2020-2034)
• Figure 36: Severity-specific cases of Presbyopia in Spain (2020-2034)
• Figure 37: Total Prevalent Cases of Presbyopia in the United kingdom (2020-2034)
• Figure 38: Total Diagnosed Prevalent cases of Presbyopia in the United Kingdom (2020-2034)
• Figure 39: Gender-specific Cases of presbyopia in the United Kingdom (2020-2034)
• Figure 40: Age-specific Cases of presbyopia in the United Kingdom (2020-2034)
• Figure 41: Severity-specific Cases of presbyopia in the United Kingdom (2020-2034)
• Figure 42: Total Prevalent Cases of Presbyopia in Japan (2020-2034)
• Figure 43: Total Diagnosed Prevalent cases of Presbyopia in Japan (2020-2034)
• Figure 44: Gender-specific cases of Presbyopia in Japan (2020-2034)
• Figure 45: Age-specific cases of Presbyopia in Japan (2020-2034)
• Figure 46: Severity-specific cases of Presbyopia in Japan (2020-2034)
• Figure 47: Patient Journey
• Figure 48: Total Seven Major Market Size, in USD million [2020-2034]
• Figure 49: 7MM-Market Size by Therapies, in USD million [2020-2034]
• Figure 50: Total Market Size in United States, in USD million [2020-2034]
• Figure 51: United States Market Size by Therapies in USD, Million [2020-2034]
• Figure 52: Total Market Size in Germany, in USD million [2020-2034]
• Figure 53: Germany Market Size by Therapies in USD, Million [2020-2034]
• Figure 54: Total Market Size in France, in USD million [2020-2034]
• Figure 55: France Market Size by Therapies, in USD million [2020-2034]
• Figure 56: Total Market Size in Italy, in USD million [2020-2034]
• Figure 57: Italy Market Size by Therapies, in USD million [2020-2034]
• Figure 58: Spain Total Market Size, in USD million [2020-2034]
• Figure 59: Spain Market Size by Therapies, in USD million [2020-2034]
• Figure 60: Total Market Size in the United Kingdom, in USD million [2020-2034]
• Figure 61: United Kingdom Market Size by Therapies in USD, Million [2020-2034]
• Figure 62: Total Market Size in Japan, in USD million [2020-2034]
• Figure 63: Market Size in Japan by Therapies, in USD million [2020-2034]
• Figure 64: SWOT Analysis
• Figure 65: Unmet Needs

Key Highlights:

• According to DelveInsight's estimates, the total diagnosed prevalent cases of presbyopia in the 7MM, were ~278 million; the number of these cases is expected to increase by 2034.
• In 2023, the market size of presbyopia was highest in the US among the 7MM, accounting for approximately USD 8,039 million which is further expected to increase by 2034.
• The current treatment for presbyopia includes VUITY (market size of ~USD 257 million in 2023, in the 7MM), an approved drug for the treatment of presbyopia.
• The different pharmacological therapies used to treat presbyopia belong mainly to classes of parasympathomimetics or cholinomimetics used for the management of the disease.
• The emerging drug Phentolamine Ophthalmic Solution 0.75% (PS) and is expected to launch in the US by 2025, in EU4 and the UK by 2026, and in Japan by 2027, which has the potential to reduce the disease burden of presbyopia in the forecasted years.

DelveInsight's "Presbyopia- Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of presbyopia, historical and forecasted epidemiology as well as the presbyopia market trends in the United States, EU4, and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

The presbyopia market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM presbyopia market size from 2020 to 2034. The Report also covers current presbyopia treatment practices, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Treatment Algorithm

Presbyopia Overview

Presbyopia is a common age-related condition characterized by a gradual loss of near-focusing ability, typically becoming noticeable after age 40 and progressing between the ages of 40 and 60. This decline in near vision results from the natural aging process, where the lenses of the eyes lose elasticity due to age-related changes in the proteins within the lens, causing it to thicken, harden, and become less flexible. These changes impair the lens's ability to refract light rays properly, diminishing the eye's focusing capacity. Presbyopia can be categorized into several types, including incipient, functional, absolute, premature, and nocturnal presbyopia. While aging is the primary risk factor for presbyopia, the condition can also manifest prematurely due to factors such as trauma, systemic diseases, cardiovascular conditions, or drug side effects. Early symptoms often include difficulty with prolonged close-up tasks and eye strain, which may worsen in dim light. Other common symptoms encompass delays in focusing at various distances, ocular discomfort, headaches, asthenopia, squinting, fatigue or drowsiness from near work, increased working distance, a need for brighter light when reading, and diplopia. Understanding these mechanisms and symptoms is crucial for the effective management and treatment of presbyopia.

Presbyopia Diagnosis

Diagnosing presbyopia involves a comprehensive eye examination by an ophthalmologist, including assessments of the retina, muscle integrity, refraction, slit-lamp evaluation, visual field, and visual acuity. An ophthalmoscope is used to examine the retina, optic disk, and choroid. Muscle integrity is assessed by observing the patient's ability to follow a moving object. Refractive tests determine how well light waves bend through the cornea and lens to identify the correct lens prescription. A slit-lamp exam provides a magnified view of the eye's anterior structures, while visual field tests measure peripheral vision, and visual acuity tests assess clarity at various distances. Pupil-dilating eye drops may be used, temporarily increasing light sensitivity. These evaluations ensure accurate diagnosis and overall ocular health.

Further details related to diagnosis are provided in the report...

Presbyopia Treatment

Treatment of presbyopia involves various options tailored to the patient's vocational and avocational needs, aiming to compensate for the eye's reduced ability to focus on nearby objects. Optical correction can be achieved through corrective eyeglasses (spectacle lenses) or contact lenses, and for those seeking more permanent solutions, refractive surgery or lens implants are viable options. Refractive surgical procedures include techniques such as Conductive Keratoplasty, LASIK, LASEK, and Photorefractive Keratectomy, which have become safer and more effective with advancements in technology. Additionally, current clinical management may involve off-label use of nonsteroidal anti-inflammatory drugs (NSAIDs), parasympathetic agonists, miotic agents, and other tempering agents. Commonly used agents in these treatments include Pilocarpine, Carbachol, Aceclidine, Brimonidine, and Nepafenac. Each treatment option is considered based on the specific needs and conditions of the patient, providing a comprehensive approach to managing presbyopia.

Presbyopia affects a significant segment of the aging population, yet existing treatments often fall short in terms of cost and accessibility. Advanced surgical options are prohibitively expensive and typically not covered by insurance, creating a barrier for many individuals. There is an urgent demand for affordable, non-invasive solutions that cater to diverse socioeconomic backgrounds.

While topical agents like pilocarpine drops, including the pioneering VUITY, represent a step forward, they have not fully met expectations. The daily cost of approximately USD 3 for a 30-day supply, coupled with a lack of insurance coverage, renders them impractical for many. Real-world feedback and AbbVie's reduction in marketing efforts underscore the need for more effective treatments with fewer applications and longer-lasting effects. Addressing these gaps is crucial for enhancing the quality of life for those affected by presbyopia.

Further details related to treatment are provided in the report...

Presbyopia Epidemiology

As the market is derived using a patient-based model, the Presbyopia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Prevalent Cases of Presbyopia, Total Diagnosed Prevalent Cases of Presbyopia, Age-specific Diagnosed Prevalent Cases of Presbyopia, Gender-specific Diagnosed Prevalent Cases of Presbyopia, and Severity-specific Diagnosed Prevalent Cases of Presbyopia, in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

• In the assessment done by DelveInsight, the estimated total prevalent cases of presbyopia in the 7MM were ~325 million in 2023.
• The highest total diagnosed prevalent cases of Presbyopia were accounted by the US in 2023 (~109 million), which is expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of presbyopia with ~32 million cases, followed by Italy, which had diagnosed prevalent population of ~24 million in 2023. On the other hand, Spain had the lowest diagnosed prevalent population (~18 million cases).
• Japan had ~50 million total diagnosed prevalent cases of Presbyopia in 2023, accounting for approximately 18% in 7MM.
• In 2023, in the US, the gender-specific diagnosed prevalent cases of presbyopia were highest for females (~60%), as compared to males (~40%), which is attributed to factors such as hormonal differences, ocular anatomy and physiology, lifestyle and occupational factors and others.
• The age-specific instances of presbyopia in the 7MM were highest for the age group 60-69 (~78 million cases), followed by the age group of less than 60 years (~77 million cases), 70-79 years (~69 million cases), and the age group =80 years (~53 million) in 2023.
• In 2023, presbyopia cases were further sub-segmented based on severity into mild and moderate to severe. Among the 7MM, the highest diagnosed prevalence was observed in moderate to severe, with ~212 million cases, compared to ~56 million mild cases.

Presbyopia Drug Chapters

The drug chapter segment of the Presbyopia report encloses a detailed analysis of Presbyopia off-label drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Presbyopia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Drugs

VUITY (pilocarpine HCI ophthalmic solution) 1.25%: Allergan/AbbVie

VUITY (pilocarpine HCI ophthalmic solution) 1.25%, developed by Allergan, is a novel treatment for presbyopia approved by the US FDA In October 2021. This prescription eye drop works by contracting the pupil to enhance near and intermediate vision without significantly affecting distance vision. By leveraging the miotic properties of pilocarpine, VUITY improves focus for close-up tasks, offering a non-invasive alternative to reading glasses. Its approval marks a significant advancement in presbyopia management, providing patients with a convenient and effective option to alleviate the condition's symptoms.

Approved but not launched yet:

QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%: Orasis Pharmaceuticals

QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%, developed by Orasis Pharmaceuticals, is a novel treatment for presbyopia that was approved by the US FDA in October 2023. This formulation aims to improve near vision by using pilocarpine, a cholinergic muscarinic agonist, to enhance the eye's accommodative ability. The market launch of QLOSI is anticipated in the second half of 2024, offering a new option for patients seeking a non-surgical approach to managing age-related vision decline.

Emerging Drugs

Brimochol PF (VT-1011): Visus Therapeutics

Brimochol PF (VT-1011), which is being developed by Visus Therapeutics, is a novel treatment for presbyopia. This investigational eye drop formulation combines brimonidine, a selective alpha-2 adrenergic agonist, with carbachol, a muscarinic agonist, to improve near vision by enhancing the eye's accommodative response. Currently, Brimochol PF is in the late stages of clinical development, having completed Phase III trials, which have demonstrated its efficacy and safety profile. The product is expected to have its New Drug Application (NDA) filed in the second half of 2024, aiming to offer a new therapeutic option for managing presbyopia.

LNZ100 - 1.75% Aceclidine: LENZ Therapeutics, Inc.

LNZ100 - 1.75% Aceclidine, developed by LENZ Therapeutics, Inc., is a promising treatment for presbyopia. This formulation utilizes Aceclidine, a parasympathomimetic agent, to improve near vision by enhancing the eye's accommodative response. Currently, LNZ100 is in advanced clinical stages, with the company planning to submit an NDA to the FDA in mid-2024. The projected market launch for LNZ100 is targeted for the second half of 2025, positioning it as a key therapeutic option for managing presbyopia.

Presbyopia Market Outlook

The market for presbyopia treatments encompasses a diverse range of options, catering to various patient preferences and needs. Non-invasive solutions, such as reading glasses, bifocals, and progressive lenses, offer clear vision at different distances, making them popular among those seeking convenience. Contact lenses, including multifocal and monovision types, further enhance flexibility and field of vision compared to traditional eyewear.

Pharmacological treatments have emerged as promising options. Eye drops like pilocarpine hydrochloride temporarily enhance near vision by constricting the pupil, thus improving depth of field. Among the notable advancements, FDA-approved treatments such as VUITY and QLOSI represent significant progress.

Despite these advancements, the market for presbyopia treatments is still evolving. The current FDA-approved therapies are limited, highlighting a significant gap in available treatment options. This gap presents opportunities for further innovation and development in the field, as there remains a substantial demand for new, effective solutions to address the diverse needs of individuals with presbyopia.

In the upcoming treatment landscape, there are a plethora of companies investigating agents for use in presbyopia which includes Visus Therapeutics and others. There are many more pharma companies which are conducting clinical trials for therapies for presbyopia.

• The therapeutic market size of presbyopia in the 7MM was approximately USD 17,000 million in 2023.
• The United States accounted for the highest market size of Presbyopia approximately 48% of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
• Among the European countries, Germany had the highest market size with nearly USD 1,666 million in 2023, while Spain had the lowest market size of Presbyopia with ~USD 938 million in 2023.
• The market size for Presbyopia in Japan was estimated to be ~USD 2642 million in 2023, which accounts for 16% of the total 7MM market.
• With the expected launch of upcoming therapies, such as LNZ100 (Aceclidine) the total market size of presbyopia is expected to show change in the upcoming years.

Presbyopia Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, LNZ100 (Aceclidine) in the US is expected to be launched by 2025 with a peak share of 2%. Aceclidine is anticipated to take 7 years to peak with a medium uptake.

Further detailed analysis of emerging therapies drug uptake in the report...

Presbyopia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Presbyopia emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Presbyopia evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from The Midwest Center for Sight, Des Plaines; University of California, San Francisco; Department of Ophthalmology, Universitatsmedizin, Mannheim; Department of Ophthalmology, University Hospital Morvan; Studi Medici Renna, Melendugno Lecce, Italy; Universidad Miguel Hernandez, Spain; Department of Ophthalmology, Kyorin University School of Medicine, Tokyo; and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Presbyopia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of presbyopia, explaining its causes, signs and symptoms, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the presbyopia market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Presbyopia market.

Presbyopia Report Insights

• Patient Population
• Therapeutic Approaches
• Presbyopia Pipeline Analysis
• Presbyopia Market Size and Trends
• Existing and Future Market Opportunities

Presbyopia Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Presbyopia Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Presbyopia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the presbyopia market share (%) distribution in 2020 and what it would look like in 2034?
• What would be the presbyopia total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest presbyopia market size during the forecast period (2024-2034)?
• At what CAGR, the presbyopia market is expected to grow at the 7MM level during the forecast period (2024-2034)?
• What would be the presbyopia market outlook across the 7MM during the forecast period (2024-2034)?
• What would be the presbyopia market growth till 2034 and what will be the resultant market size in the year 2034?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risk, burden, and unmet needs of presbyopia?
• What is the historical presbyopia patient population in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan?
• What would be the forecasted patient population of presbyopia at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to presbyopia?
• Out of the above-mentioned countries, which country would have the highest prevalent population of presbyopia during the forecast period (2024-2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2024-2034)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of presbyopia along with the approved therapy?
• What are the current treatment guidelines for the treatment of presbyopia in the US, Europe, And Japan?
• What are the presbyopia-marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of presbyopia?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of presbyopia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the presbyopia therapies?
• What are the recent therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the clinical studies going on for presbyopia and their status?
• What are the key designations that have been granted for the emerging therapies for presbyopia?
• What are the 7MM historical and forecasted market of presbyopia?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the presbyopia Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and potential of current and emerging therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What is the forecast period covered in the report?

The presbyopia Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the presbyopia market?

The presbyopia market is quite robust. The major layers are Visus Therapeutics, LENZ Therapeutics, Inc., Glaukos Corporation, and others which are currently developing drugs for the treatment of presbyopia.

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the presbyopia market?

The increase in diagnosed prevalent cases of presbyopia and the launch of emerging therapies are attributed to be the key drivers for increasing the presbyopia market.

5. What is the expected impact of emerging therapies or advancements in presbyopia treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the presbyopia treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the presbyopia market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Presbyopia Market Overview at a Glance

3.1.. Market Share (%) Distribution of Presbyopia by Therapies in 2020

3.2.. Market Share (%) Distribution of Presbyopia by Therapies in 2034

4. Presbyopia Market: Future Perspective

5. Executive Summary of Presbyopia

6. Key Events

7. Disease Background and Overview

7.1.. Introduction

• 7.2. Signs and Symptoms of Presbyopia

7.3.. Difference between Presbyopia and Hyperopia

7.4.. Risk Factors and Causes of Presbyopia

7.5.. Pathophysiology of Presbyopia

7.6.. Complications of Presbyopia

7.7.. Diagnosis of Presbyopia

7.7.1.. Patient History

7.7.2.. Ocular Examination

7.7.3.. Supplemental Testing

7.7.4.. Eye health evaluation

7.7.5.. Recommended eye examination frequency for pediatric patients and adults

• 7.8. Differential Diagnosis

7.7.. Early Detection and Prevention of Presbyopia

7.8.. Current Treatment Practices: Presbyopia

7.8.1.. Treatment Algorithm of Presbyopia

7.8.2.. Optical Correction with Spectacle Lenses

7.8.3.. Optical Correction with Contact Lenses

7.8.4.. Surgical options

7.8.5.. Corneal inlay

7.8.6.. Lens implants

7.8.7.. Treatment Algorithm

• 7.8.8. Guidelines of Presbyopia

7.8.1.. Management Strategies for Correction of Presbyopia- American Optometric Association

7.8.2.. NICE guidance for corneal inlay implantation for correction of presbyopia

7.8.3.. Management guidelines by the American Academy of Ophthalmology

7.8.4.. Analysis of Guidelines

8. Epidemiology and Patient Population

8.1.. Key Findings

8.2.. Methodology of Epidemiology

8.3.. Assumptions and Rationale: 7MM

8.4.. Total Diagnosed Prevalent Cases of Presbyopia in the 7MM

• 8.5. The United States
  • 8.5.1. Total Prevalent Cases of Presbyopia in the United States (2020-2034)
  • 8.5.2. Total Diagnosed Prevalent Cases of Presbyopia in the United States (2020-2034)
  • 8.5.3. Gender-specific cases of Presbyopia in the United States (2020-2034)
  • 8.5.4. Age-specific cases of Presbyopia in the United States (2020-2034)
  • 8.5.5. Severity-specific cases of Presbyopia in the United States (2020-2034)
• 8.6. EU4 and the UK
  • 8.6.1. Germany
    • 8.6.1.1. Total Prevalent Cases of Presbyopia in Germany (2020-2034)
    • 8.6.1.2. Total Diagnosed Prevalent Cases of Presbyopia in Germany (2020-2034)
    • 8.6.1.3. Gender-specific cases of Presbyopia in Germany (2020-2034)
    • 8.6.1.4. Age-specific cases of Presbyopia in Germany (2020-2034)
    • 8.6.1.5. Severity-specific cases of Presbyopia in Germany (2020-2034)
  • 8.6.2. France
    • 8.6.2.1. Total Prevalent Cases of Presbyopia in France (2020-2034)
    • 8.6.2.2. Total Diagnosed Prevalent Cases of Presbyopia in France (2020-2034)
    • 8.6.2.3. Gender-specific cases of Presbyopia in France (2020-2034)
    • 8.6.2.4. Age-specific cases of Presbyopia in France (2020-2034)
    • 8.6.2.5. Severity-specific cases of Presbyopia in France (2020-2034)
  • 8.6.3. Italy
    • 8.6.3.1. Total Prevalent Cases of Presbyopia in Italy (2020-2034)
    • 8.6.3.2. Total Diagnosed Prevalent Cases of Presbyopia in Italy (2020-2034)
    • 8.6.3.3. Gender-specific cases of Presbyopia in Italy (2020-2034)
    • 8.6.3.4. Age-specific cases of Presbyopia in Italy (2020-2034)
    • 8.6.3.5. Severity-specific cases of Presbyopia in Italy (2020-2034)
  • 8.6.4. Spain
    • 8.6.4.1. Total Prevalent Cases of Presbyopia in Spain (2020-2034)
    • 8.6.4.2. Total Diagnosed Prevalent Cases of Presbyopia in Spain (2020-2034)
    • 8.6.4.3. Gender-specific cases of Presbyopia in Spain (2020-2034)
    • 8.6.4.4. Age-specific cases of Presbyopia in Spain (2020-2034)
    • 8.6.4.5. Severity-specific cases of Presbyopia in Spain (2020-2034)
  • 8.6.5. The United Kingdom
    • 8.6.5.1. Total Prevalent Cases of Presbyopia in the United Kingdom (2020-2034)
    • 8.6.5.2. Total Diagnosed Prevalent Cases of Presbyopia in the United Kingdom (2020-2034)
    • 8.6.5.3. Gender-specific Cases of Presbyopia in the United Kingdom (2020-2034)
    • 8.6.5.4. Age-specific Cases of presbyopia in the United Kingdom (2020-2034)
    • 8.6.5.5. Severity-specific Cases of presbyopia in the United Kingdom (2020-2034)
  • 8.6.6. Japan
    • 8.6.6.1. Total Prevalent Cases of Presbyopia in Japan (2020-2034)
    • 8.6.6.2. Total Diagnosed Prevalent Cases of Presbyopia in Japan (2020-2034)
    • 8.6.6.3. Gender-specific cases of Presbyopia in Japan (2020-2034)
    • 8.6.6.4. Age-specific cases of Presbyopia in Japan (2020-2034)
    • 8.6.6.5. Severity-specific cases of Presbyopia in Japan (2020-2034)

9. Patient Journey

10. Marketed Drugs

• 10.1. VUITY (pilocarpine HCI ophthalmic solution) 1.25%: Allergan/AbbVie
  • 10.1.1. Product Description
  • 10.1.2. Regulatory Milestones
  • 10.1.3. Other Developmental Activities
  • 10.1.4. Clinical Trials Information
  • 10.1.5. Safety and Efficacy

11. Key Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Brimochol PF (VT-1011): Visus Therapeutics
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analysts' Views
• 11.3. LNZ100 - 1.75% Aceclidine: LENZ Therapeutics, Inc.
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analysts' Views

To be continued in the report

12. Presbyopia: Seven Major Market Analysis

• 12.1. Key Findings: Market
• 12.2. Market Outlook
• 12.3. Key Market Forecast Assumptions
• 12.4. Conjoint Analysis
• 12.5. Total Market Size of presbyopia in the 7MM
• 12.6. Market Size of presbyopia by Therapies in the 7MM
• 12.7. The United States
  • 12.7.1. Total Market Size of presbyopia
  • 12.7.2. Market Size of presbyopia by Therapies
• 12.8. EU4 and the UK
  • 12.8.1. Germany
    • 12.8.1.1. Total Market Size of Presbyopia
    • 12.8.1.2. Market Size of Presbyopia by Therapies
  • 12.8.2. France
    • 12.8.2.1. Total Market Size of Presbyopia
    • 12.8.2.2. Market Size of Presbyopia by Therapies
  • 12.8.3. Italy
    • 12.8.3.1. Total Market Size of Presbyopia
    • 12.8.3.2. Market Size of Presbyopia by Therapies
  • 12.8.4. Spain
    • 12.8.4.1. Total Market Size of Presbyopia
    • 12.8.4.2. Market Size of Presbyopia by Therapies
  • 12.8.5. The United Kingdom
    • 12.8.5.1. Total Market Size of Presbyopia
    • 12.8.5.2. Market Size of Presbyopia by Therapies
• 12.9. Japan
  • 12.9.1. Total Market Size of Presbyopia
  • 12.9.2. Market Size of Presbyopia by Therapies

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations

18. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight